OKUR

OnKure TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$7.00

+66.7% vs current

Most likely

Base case

50%

Probability

Target price

$4.00

-4.8% vs current

B-

Bear case

25%

Probability

Target price

$2.00

-52.4% vs current

AI sentiment snapshot

Latest data as of 2026-06-26

AI commentary

Primary-source evidence quality is strong, but the information set remains narrow: no recent trusted-news packet, no usable social coverage packet, thin analyst-context support, and no direct PI3Kα peer set in the packet. Sentiment therefore leans cautious-to-negative, consistent with the deterministic directional prior, because the story is dominated by long-dated biotech milestones rather than near-term operating beats.

RankAlpha Sentiment Codex - 2026-06-26

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-09-30catalystRunway reduces immediate financing pressure but does not remove development riskHigh impact

The company reported $192.1 million of cash as of March 31, 2026 and said that cash is expected to fund operations into 2029 following the $150 million private placement, which lowers near-term dilution pressure but shifts focus to milestone execution [#SEC-8K-2026-05-05].

2026-12-31eventPIKture-01 data update remains a key proof pointHigh impact

Management said it plans to report PIKture-01 data by the end of 2026, which is important because OKI-219 is no longer being advanced independently and positive translational or activity signals could still influence platform credibility and partnering optionality [#SEC-8K-2026-05-05] [#PR-EARNINGS-2026-05-06].

2027-06-30catalystNext-generation PI3Kα programs progress toward INDs in H1 2027High impact

OnKure said OKI-355 in vascular anomalies and OKI-345 in breast cancer are the strategic focus, with both IND submissions planned for the first half of 2027; execution against these timelines is the main long-duration value driver [#SEC-8K-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-26 • Updated nightlySource: Internal modelMethodology